A Rare Case of Pembrolizumab-Associated Graves’ Disease

Immune checkpoint inhibitors (ICPis), such as pembrolizumab (Keytruda®), are associated with the development of several immune-related adverse events (irAEs). Thyroid dysfunction is a common endocrine irAE associated with pembrolizumab; however, Graves’ disease induced by pembrolizumab is extremely...

Descripción completa

Detalles Bibliográficos
Autores principales: Alqaisi, Sura, Rahman, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998112/
https://www.ncbi.nlm.nih.gov/pubmed/36909047
http://dx.doi.org/10.7759/cureus.34696
_version_ 1784903401492971520
author Alqaisi, Sura
Rahman, Ali
author_facet Alqaisi, Sura
Rahman, Ali
author_sort Alqaisi, Sura
collection PubMed
description Immune checkpoint inhibitors (ICPis), such as pembrolizumab (Keytruda®), are associated with the development of several immune-related adverse events (irAEs). Thyroid dysfunction is a common endocrine irAE associated with pembrolizumab; however, Graves’ disease induced by pembrolizumab is extremely rare. Few cases of this condition have been reported in the literature. Here, we report the case of a 50-year-old patient who presented with thyrotoxicosis that was attributed to Graves’ disease secondary to pembrolizumab therapy.
format Online
Article
Text
id pubmed-9998112
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-99981122023-03-10 A Rare Case of Pembrolizumab-Associated Graves’ Disease Alqaisi, Sura Rahman, Ali Cureus Endocrinology/Diabetes/Metabolism Immune checkpoint inhibitors (ICPis), such as pembrolizumab (Keytruda®), are associated with the development of several immune-related adverse events (irAEs). Thyroid dysfunction is a common endocrine irAE associated with pembrolizumab; however, Graves’ disease induced by pembrolizumab is extremely rare. Few cases of this condition have been reported in the literature. Here, we report the case of a 50-year-old patient who presented with thyrotoxicosis that was attributed to Graves’ disease secondary to pembrolizumab therapy. Cureus 2023-02-06 /pmc/articles/PMC9998112/ /pubmed/36909047 http://dx.doi.org/10.7759/cureus.34696 Text en Copyright © 2023, Alqaisi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Alqaisi, Sura
Rahman, Ali
A Rare Case of Pembrolizumab-Associated Graves’ Disease
title A Rare Case of Pembrolizumab-Associated Graves’ Disease
title_full A Rare Case of Pembrolizumab-Associated Graves’ Disease
title_fullStr A Rare Case of Pembrolizumab-Associated Graves’ Disease
title_full_unstemmed A Rare Case of Pembrolizumab-Associated Graves’ Disease
title_short A Rare Case of Pembrolizumab-Associated Graves’ Disease
title_sort rare case of pembrolizumab-associated graves’ disease
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998112/
https://www.ncbi.nlm.nih.gov/pubmed/36909047
http://dx.doi.org/10.7759/cureus.34696
work_keys_str_mv AT alqaisisura ararecaseofpembrolizumabassociatedgravesdisease
AT rahmanali ararecaseofpembrolizumabassociatedgravesdisease
AT alqaisisura rarecaseofpembrolizumabassociatedgravesdisease
AT rahmanali rarecaseofpembrolizumabassociatedgravesdisease

Ejemplares similares